Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Sangamo Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference


Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that management will present a corporate overview at the 39th Annual J.P. Morgan Healthcare Conference on Wednesday, January 13th at 5:20pm EST.

The virtual session will be webcast live and may be accessed via a link on the Sangamo Therapeutics website in the Investors and Media section under Events and Presentations. The presentation will also be available on the Sangamo website after the event.

About Sangamo Therapeutics

Sangamo Therapeutics is committed to translating ground-breaking science into genomic medicines with the potential to transform patients’ lives using gene therapy, ex vivo gene-edited cell therapy, and in vivo genome editing and genome regulation. For more information about Sangamo, visit www.sangamo.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210105005148/en/

Sangamo Therapeutics Inc. Stock

€0.48
-0.950%
The price for the Sangamo Therapeutics Inc. stock decreased slightly today. Compared to yesterday there is a change of -€0.005 (-0.950%).
With 11 Buy predictions and 12 Sell predictions the community is currently undecided on Sangamo Therapeutics Inc..
However, we have a potential of 316.58% for Sangamo Therapeutics Inc. as the target price of 2 € is above the current price of 0.48 €.
Like: 0
Share
Business Wire, a Berkshire Hathaway company, is the global leader in press release distribution and regulatory disclosure. Investor relations, public relations, public policy and marketing professionals rely on Business Wire for secure and accurate distribution of market-moving news and multimedia.

Legal notice

Comments